Ironwood Pharmaceuticals
IRWD
145 hedge funds and large institutions have $1.55B invested in Ironwood Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 50 increasing their positions, 40 reducing their positions, and 35 closing their positions.
170% more call options, than puts
Call options by funds: $18.5M | Put options by funds: $6.84M
25% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 40
2.68% more ownership
Funds ownership: 124.76% → 127.44% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less funds holding
Funds holding: 151 → 145 (-6)
14% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 35
42% less capital invested
Capital invested by funds: $2.69B → $1.55B (-$1.14B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$50.4M |
| 2 |
BM
Bridger Management
New York
|
+$48.8M |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$39.5M |
| 4 |
UBS AM
Chicago,
Illinois
|
+$16.2M |
| 5 |
Millennium Management
New York
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$79.9M |
| 2 |
O
OppenheimerFunds
New York
|
-$53M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$31.5M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$28.1M |
| 5 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$22.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
US Bancorp
Minneapolis,
Minnesota
| – | -$1K | -86 | Closed |
|
|
IA
177
IFP Advisors
Tampa,
Florida
| – | -$1K | -59 | Closed |
|
|
ML
178
McAdam LLC
Philadelphia,
Pennsylvania
| – | -$1K | -36 | Closed |
|
|
AIA
179
Alera Investment Advisors
Deerfield,
Illinois
| – | +$310 | +27 | New |
|
|
PCG
180
Private Capital Group
West Hartford,
Connecticut
| – | +$620 | +54 | New |
|
IRWD Hedge Fund Activity: Q4 2018 in Review
145 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q4 2018, worth a combined $1.55B — down 42% from $2.69B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of IRWD and 30 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 50 added.
The largest buyer was Brown Capital Management, adding an estimated $50.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $79.9M.
- 145 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q4 2018, down from 151 in Q3 2018.
- Funds reported $1.55B of Ironwood Pharmaceuticals stock for Q4 2018, down 42% quarter-over-quarter.
- 30 funds opened new Ironwood Pharmaceuticals positions in Q4 2018 and 35 closed out, a net change of -5 holders.
- The largest Ironwood Pharmaceuticals buyer in Q4 2018 was Brown Capital Management, an estimated $50.4M added.
- The largest Ironwood Pharmaceuticals seller in Q4 2018 was T. Rowe Price Associates, an estimated $79.9M sold.
Based on aggregated 13F filings for Q4 2018.